Mesenchymal Stem Cells not checked
PT. Prodia Stem Cell Indonesia
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.”In the company’s words, NCT04340609 on ClinicalTrials.gov
- Tested for
- Acute Myocardial Infarction
- Main trialPhase 1/2
- “The study will perform UC-MSCs transplantation in 2 groups and 1 control group with standard treatment. Each group consists of 5 subjects. In the first group UC-MSCs will be transplanted via intravenous (IV) route and the second group via intracoronary (IC) route. The IV group will receive 2 million cells/kg for each subject and the dosage of IC group is 50 million cells for each subject. All groups will be observed until 1 year.”In the company’s words, NCT04340609 on ClinicalTrials.gov
Other drugs for Acute Myocardial Infarction
- InclisiranNovartis · Phase 3
- ZalunfibanCeleCor Therapeutics · Phase 3
- SGC001Beijing Sungen Biomedical Technology Co., Ltd · Phase 2
- UMSC01Ever Supreme Bio Technology Co., Ltd. · Phase 2
- XolatrypNyrada Pty Ltd · Phase 2
- NL005Beijing Northland Biotech. Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 8 Apr 2021 | Stem Cell in Acute Myocardial Infarction |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026